Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.

Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T.

Int J Rheum Dis. 2019 Apr;22(4):574-582. doi: 10.1111/1756-185X.13401. Epub 2018 Oct 18.

PMID:
30338649
2.

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.

Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y.

Clin Immunol. 2018 Jun;191:67-74. doi: 10.1016/j.clim.2018.03.018. Epub 2018 Mar 31.

PMID:
29614335
3.

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.

Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):834-841. Epub 2016 Aug 31.

PMID:
27607196
4.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.

Hirata S, Li W, Kubo S, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux NA, Tanaka Y.

Mod Rheumatol. 2016 Nov;26(6):850-856. doi: 10.3109/14397595.2016.1153449. Epub 2016 Mar 30.

PMID:
26873570
5.

Histamine inhibits differentiation of skin fibroblasts into myofibroblasts.

Lin L, Yamagata K, Nakayamada S, Sawamukai N, Yamaoka K, Sakata K, Nakano K, Tanaka Y.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):434-9. doi: 10.1016/j.bbrc.2015.05.094. Epub 2015 May 31.

PMID:
26036574
6.

Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus.

Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y.

Rheumatology (Oxford). 2015 Mar;54(3):405-12. doi: 10.1093/rheumatology/keu343. Epub 2014 Sep 2.

PMID:
25183834
7.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.

Ann Rheum Dis. 2015 Feb;74(2):389-95. doi: 10.1136/annrheumdis-2013-204016. Epub 2013 Nov 28. Erratum in: Ann Rheum Dis. 2016 Jul;75(7):e46.

8.

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.

Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Arthritis Res Ther. 2013 Sep 25;15(5):R135. doi: 10.1186/ar4315.

9.

Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.

Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Y, Tanaka Y.

Mod Rheumatol. 2014 Jan;24(1):42-51. doi: 10.3109/14397595.2013.854051.

PMID:
24261758
10.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
11.

Efficacy and safety of reducing duration of infliximab infusion.

Fukuyo S, Saito K, Yamaoka K, Sawamukai N, Hirata S, Nawata M, Iwata S, Tanaka Y.

Mod Rheumatol. 2014 Mar;24(2):275-80. doi: 10.3109/14397595.2013.843747. Epub 2013 Oct 11.

PMID:
24251990
12.

Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis.

Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y.

Mod Rheumatol. 2013 Nov;23(6):1151-7. doi: 10.1007/s10165-012-0813-8. Epub 2012 Dec 28.

PMID:
23271169
13.

Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.

Sawamukai N, Satake A, Schmidt AM, Lamborn IT, Ojha P, Tanaka Y, Kambayashi T.

Blood. 2012 Jun 7;119(23):5575-83. doi: 10.1182/blood-2011-07-367987. Epub 2012 Apr 10.

14.

Involvement of mast cells in systemic sclerosis.

Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(2):81-6. Review.

15.

C5a promotes migration, proliferation, and vessel formation in endothelial cells.

Kurihara R, Yamaoka K, Sawamukai N, Shimajiri S, Oshita K, Yukawa S, Tokunaga M, Iwata S, Saito K, Chiba K, Tanaka Y.

Inflamm Res. 2010 Aug;59(8):659-66. doi: 10.1007/s00011-010-0178-4. Epub 2010 Mar 9.

16.

Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling.

Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y.

Arthritis Rheum. 2010 Apr;62(4):952-9. doi: 10.1002/art.27331.

17.

Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.

Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y.

J Rheumatol. 2010 Mar;37(3):512-20. doi: 10.3899/jrheum.090048. Epub 2010 Jan 15.

18.

Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.

Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y.

J Immunol. 2007 Nov 15;179(10):6479-84.

19.

Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.

Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri Y, Kohro T, Wada Y, Kodama T, Tanaka Y.

Rheumatology (Oxford). 2007 Apr;46(4):597-603. Epub 2006 Oct 24.

PMID:
17062647
20.

Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.

Wang B, Tsukada J, Higashi T, Mizobe T, Matsuura A, Mouri F, Sawamukai N, Ra C, Tanaka Y.

Genes Cells. 2006 Sep;11(9):983-92.

21.

[Active arthritis due to cryoglobulinemia based on HCV infection in a patient with RA improvement of arthritis with IFN-alpha].

Tsujimura S, Saito K, Tokunaga M, Nakatsuka K, Nakayamada S, Nakano K, Sawamukai N, Nawata M, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2004 Feb;27(1):48-53. Japanese.

22.

Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial.

Nakayamada S, Saito K, Nakatsuka K, Nakano K, Tokunaga M, Sawamukai N, Tsujimura S, Nawata M, Tanaka Y.

Mod Rheumatol. 2003 Dec;13(4):339-45. doi: 10.3109/s10165-003-0247-4.

PMID:
24387256

Supplemental Content

Loading ...
Support Center